Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mds645PMID 23337633PMCID PMC6267878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  2011cited by this paper
• Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

  2011cited by this paper
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

  2011cited by this paper
• Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

  2010cited by this paper
• Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

  2010cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature

  2010cited by this paper
• Rapport 2009 sur l’état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein

  2010cited by this paper
• Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study

  2010cited by this paper
• The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

  2009cited by this paper
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

  2009cited by this paper
• Repeatability of published microarray gene expression analyses

  2009cited by this paper
• Use of archived specimens in evaluation of prognostic and predictive biomarkers.

  2009cited by this paper
• Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

  2009cited by this paper
• Gene-expression signatures in breast cancer.

  2009cited by this paper
• Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

  2008cited by this paper
• The influence of a Gene expression profile on breast cancer decisions

  2008cited by this paper
• Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• Interpretation of microarray data in cancer

  2007cited by this paper
• Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools

  2007cited by this paper
• Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.

  2007cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

  2006cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy

  2005cited by this paper
• Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Gene-expression signatures in breast cancer.

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• The Delphi method : techniques and applications

  1976cited by this paper

• Pruebas moleculares para cáncer de mama: Revisión sistemática de la disponibilidad en países de latinoamérica y el caribe

  2024cites this paper
• Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients

  2024cites this paper
• Young Women with Breast Cancer: The Current Role of Precision Oncology

  2023cites this paper
• [Use of genome-wide testing in oncology: French expert opinion based on the Delphi methodology].

  2023cites this paper
• Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?

  2023cites this paper
• Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

  2023cites this paper
• Immunohistochemical Subtypes of The Breast Cancer in The Ultrasound and Clinical Aspect – Literature Review

  2022cites this paper
• Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature

  2022cites this paper
• Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer

  2021cites this paper
• Invited Review The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer

  2021cites this paper
• Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders

  2021cites this paper
• Therapeutische Grundlagen in der gynäkologischen Onkologie

  2021cites this paper
• Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

  2021cites this paper
• Circulating circTOLLIP serves as a diagnostic biomarker for liquid biopsy in non-small cell lung cancer.

  2021cites this paper
• Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.

  2020cites this paper
• Combining gene expression signature with clinical features for survival stratification of gastric cancer.

  2020cites this paper
• Molecular profiling in breast cancer—ready for clinical routine?

  2020cites this paper
• 'Essentials of Cancer Genomic, Computational Approaches and Precision Medicine

  2020cites this paper
• Combining Gene Expression Signature With Clinical Features for Survival Strati�cation of Gastric Cancer

  2020cites this paper
• Molecular Profiling of Breast Cancer in Clinical Trials: A Perspective

  2020cites this paper
• Optical metabolic imaging of hypoxic exposure in breast cancer cells of varying metastatic potential

  2020cites this paper
• PREDICTIVE RELAPSE MODEL IN PATIENTS WITH LUMINAL HER2-NEGATIVE BREAST CANCER

  2020cites this paper
• Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Mammaprint™: a comprehensive review.

  2019cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR

  2019cites this paper
• Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosis.

  2019cites this paper
• PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement

  2019cites this paper
• An integrative view on breast cancer signature panels

  2019cites this paper
• A breast multi‐disciplinary genomic tumor board is feasible and can provide timely and impactful recommendations

  2018cites this paper
• [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].

  2018cites this paper
• Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer

  2018cites this paper
• Evaluation of non-genomic, clinical risk and survival results in endocrine-sensitive, HER2-negative, lymph node negative breast cancer

  2018cites this paper
• Genomic Pathology: Training for New Technology

  2018cites this paper
• Genomic Applications in Breast Carcinoma

  2018cites this paper
• Evaluation of non-genomic, clinical risk and survival results in endocrine-sensitive, HER-2 negative, lymph node negative breast cancer.

  2018cites this paper
• Tumor Profiling, Gene Expression Assays and Molecular Diagnostic Testing for Hematology/Oncology Indications

  2017cites this paper
• Targeting PI3K/AKT/mTOR Pathway

  2017cites this paper
• Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer

  2017cites this paper
• [Validation and clinical application of MammaPrint® in patients with breast cancer].

  2017cites this paper
• Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions

  2017cites this paper
• Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

  2017cites this paper
• Opening the Regulatory Black Box of Clinical Cancer Research: Transnational Expertise Networks and “Disruptive” Technologies

  2017cites this paper
• Clinical utility of gene-expression signatures in early stage breast cancer

  2017cites this paper
• Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.

  2017cites this paper
• Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression

  2017cites this paper
• Validación y aplicación clínica de MammaPrint® en pacientes con cáncer de mama

  2017cites this paper
• Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract

  2017cites this paper
• Molecular Classification and Testing of Breast Carcinoma

  2017cites this paper
• Risikoadaptierte Diagnostik und Therapie

  2017cites this paper
• Molecular Tests for the Choice of Cancer Therapy.

  2017cites this paper
• Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors

  2017cites this paper
• Opening the Regulatory Black Box of Clinical Cancer Research: Transnational Expertise Networks and “Disruptive” Technologies

  2017cites this paper
• Pathology and Molecular Pathology of Breast Cancer

  2017cites this paper
• The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

  2016cites this paper
• Pharmacogenetics and pharmacogenomics as tools in cancer therapy

  2016influential citation
• MicroRNA regulation in breast cancer - a Bayesian analysis of expression data

  2016cites this paper
• New era of integrated cancer biomarker discovery using reverse-phase protein arrays.

  2016cites this paper
• Adjuvant chemotherapy in early breast cancer.

  2016cites this paper
• The current use and attitudes towards tumor genome sequencing in breast cancer

  2016cites this paper
• The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer

  2016cites this paper
• Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example

  2016cites this paper
• Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice

  2016cites this paper
• Comparative Effectiveness of Biomarkers to Target Cancer Treatment

  2016cites this paper
• News on the medical treatment of young women with early-stage HER2-negative breast cancer

  2016cites this paper
• The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

  2016cites this paper
• Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor.

  2016cites this paper
• Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer.

  2016cites this paper
• Genome-wide analysis of microRNA and mRNA expression signatures in cancer

  2015cites this paper
• A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer

  2015cites this paper
• Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?

  2015cites this paper
• Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?

  2015cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cites this paper
• Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study

  2015cites this paper
• [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].

  2015cites this paper
• Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis

  2015cites this paper
• Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria

  2015cites this paper
• Closing the Gap between Knowledge and Clinical Application: Challenges for Genomic Translation

  2015cites this paper
• Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.

  2015cites this paper
• Androgen receptor and antiandrogen therapy in male breast cancer.

  2015cites this paper
• Factors affecting the adoption and use of gene expression profiling by oncologists in clinical practice.

  2015cites this paper
• Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers.

  2015cites this paper
• Aneuploidy identifies subsets of patients with poor clinical outcome in grade 1 and grade 2 breast cancer.

  2015cites this paper
• Aromatase inhibitors in male breast cancer: a pooled analysis

  2015cites this paper
• Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.

  2015cites this paper
• Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico

  2015cites this paper
• Hormone Therapy for Breast Cancer in Men.

  2015cites this paper
• [Molecular signatures of breast cancer: What clinical utility?].

  2015cites this paper
• [Genomic signature of breast cancer: The quest for the Holy Grail].

  2015cites this paper
• Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.

  2015cites this paper
• Molecular markers for breast cancer diagnosis, prognosis and targeted therapy

  2015cites this paper
• Genomic medicine and risk prediction across the disease spectrum

  2015cites this paper
• Reply to V.P. Retèl et al, D. Gauchan et al, and C. Rahilly-Tierney et al.

  2015cites this paper
• Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

  2015cites this paper
• Klinische Versorgungsforschung beim Mammakarzinom

  2015cites this paper
• Design and Analysis of Clinical Trials for Predictive Medicine

  2015cites this paper
• uPA/PAI-1, Oncotype DX™, MammaPrint®. Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein☆◊

  2015cites this paper
• Les signatures moléculaires commerciales : quelle utilité clinique ?

  2015cites this paper
• Utiliser une signature moléculaire pour la prise en charge d'une patiente atteinte d'un cancer du sein : la quête du Graal…

  2015cites this paper
• New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

  2014cites this paper